Dr. Klempner on the Significance of KRYSTAL-1 Data in KRAS G12C–Mutant CRC
November 9th 2022Sam Klempner, MD, discusses the incidence of KRAS G12C mutations in patients with metastatic colorectal cancer, the viability of the target in this disease, the efficacy of adagrasib in combination with cetuximab in this patient population, and the importance of genetic testing.
Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC
August 12th 2022Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.
KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC
July 1st 2022Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.